Movement Disorders

Neurology News Network for the week ending December 23, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 22, 2023.

Researchers have successfully grown norepinephrine neurons from stem cells, which are critical for regulating various bodily functions, offering new insights into neurodegenerative diseases such as Alzheimer and Parkinson.

The research aimed to assess FMD prevalence and clinical manifestations in both elderly and younger onset individuals, revealing insights into symptom variations across different age groups.

According to a recent study, investigators found no reports of moderate or severe adverse events with a high dose of nicotinamide riboside therapy in patients with Parkinson disease.

In newly released data, AMT-130 showed a manageable safety profile at both low and high doses in patients with Huntington disease, supporting the gene therapy's continued development.

A recent systematic practice review outlined pragmatic recommendations to enhance palliative care for patients with Parkinson disease and their caregivers, emphasizing integration, coordination, and personalized care plans.

In a recent case study of a 32-year-old man diagnosed with Friedreich ataxia, parental sample testing identified a novel intragenic deletion involving the 5'UTR upstream region and exons 1 and 2 of the FXN gene.

The expert neurologists discuss non-motor symptoms of Parkinson’s disease: types, their impact on patient’s quality of life, and current and emerging treatment options for non-motor symptoms.

A new retrospective analysis revealed that modifying advanced therapies led to improved motor and subjective symptoms, emphasizing the importance of considering combination therapies when efficacy declines or adverse events arise.

A-synuclein-positive athletes were similar to α-synuclein-negative athletes on demographics and other serum and blood biomarkers; however, these patients had lower grey matter volumes in the right inferior orbitofrontal, right anterior insula, and right olfactory cortices.

Daniel Claassen, MD, MS, reviews emerging treatment options for HD, and shares resources for patients, caregivers, and physicians to navigate diagnosis and management of HD.

An expert neurologist comments on the lack of an approved treatment for HD and examines the evolving treatment landscape, including interest in biomarkers.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is ataxia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 15, 2023.

In a recent analysis, acute levodopa induced a robust short-duration response (SDR) and long-duration response (LDR), with further improvement in the combined SDR plus LDR state in patients with Parkinson disease.

The neurology doctors discuss motor fluctuations and dyskinesia associated with Parkinson’s Disease.

New preliminary data showed that more than 50% of dosed pediatric patients with X-linked myotubular myopathy achieved ventilator independence, with some attaining the ability to walk independently.

In a recently published study, findings revealed that mitochondrial dysfunction in patients with idiopathic REM sleep behavior disorder may serve as a predictor for the progression of Parkinson disease.

Lobule VIIB showed a non-linear pattern of lower volume with each Hoehn and Yahr-increment bilaterally, with the most significant group differences at stages 4-5 compared with controls.

Also known as ATH-1017, fosgonimeton demonstrated a safe profile, with directional improvements in cognitive, functional, and biomarker assessments.

The OneRF Ablation System follows the Evo cortical and sEEG electrode product lines, marking a significant step in NeuroOne's journey to offer innovative solutions for neurological conditions.

Maura McCarthy, head of corporate development at Skyhawk Therapeutics, provided comment on a new phase 1 study assessing SKY-0515, a small molecule candidate as a potential treatment for Huntington disease.

Daniel Claassen, MD, MS, emphasizes the utilization of social workers to reduce the psychosocial burden of HD on both the patient and their family.